N-methyl-d-aspartate glutamate receptor (NMDA-R) antibodies in mild cognitive impairment and dementias

Neuroscience Research

Volumn 85, Issue , 2014, Pages 58-64

  Busse, Stefan ^a   Brix, Britta ^b   Kunschmann, Ralf ^a   Bogerts, Bernhard ^a,c   Stoecker, Winfried ^b   Busse, Mandy ^d  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Institute of Experimental Immunology   (Germany)

^c Center for Behavioral Brain Sciences   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Alzheimer's disease (AD); Frontotemporal dementia (FTD); Lewy body disease (LBD); Mild cognitive impairment (MCI); NMDA receptor antibodies; Subcortical ischemic vascular dementia (SIVD)

Indexed keywords

AUTOANTIBODY; GLUTAMATE RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; N METHYL DEXTRO ASPARTATE GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIGEN;

AGED; ALZHEIMER DISEASE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PSYCHOSIS; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84908397205     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2014.06.002     Document Type: Article

References (84)

1. Aarsland D., Ballard C., Walker Z., Bostrom F., Alves G., Kossakowski K., Leroi I., Pozo-Rodriguez F., Minthon L., Londos E. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009, 8:613-618.
2. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008, 58:1130-1135.
3. Diagnostic and Statistical Manual of Mental Disorders 2000, A.P. Association (Ed.).
4. Ballard C., Neill D., O'Brien J., McKeith I.G., Ince P., Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J. Affect. Disord. 2000, 59:97-106.
5. Ballard C., O'Brien J., Coope B., Fairbairn A., Abid F., Wilcock G. A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. Int. Psychogeriatr. (IPA) 1997, 9:57-64.
6. Ballard C.G., O'Brien J.T., Swann A.G., Thompson P., Neill D., McKeith I.G. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. J. Clin. Psychiatry 2001, 62:46-49.
7. Barnes D.E., Yaffe K., Byers A.L., McCormick M., Schaefer C., Whitmer R.A. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch. Gen. Psychiatry 2012, 69:493-498.
8. Baskys A., Cheng J.X. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. Exp. Gerontol. 2012, 47:887-891.
9. Blass D.M., Rabins P.V. Depression in frontotemporal dementia. Psychosomatics 2009, 50:239-247.
10. Boeve B.F. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism Relat. Disord. 2012, 1(18 Suppl.):S41-S44.
11. Boot B.P., Orr C.F., Ahlskog J.E., Ferman T.J., Roberts R., Pankratz V.S., Dickson D.W., Parisi J., Aakre J.A., Geda Y.E., Knopman D.S., Petersen R.C., Boeve B.F. Risk factors for dementia with Lewy bodies: a case-control study. Neurology 2013, 81:833-840.
12. Boxer A.L., Lipton A.M., Womack K., Merrilees J., Neuhaus J., Pavlic D., Gandhi A., Red D., Martin-Cook K., Svetlik D., Miller B.L. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord. 2009, 23:211-217.
13. Boyce-Rustay J.M., Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006, 31:2405-2414.
14. Busse S., Busse M., Brix B., Probst C., Genz A., Bogerts B., Stoecker W., Steiner J. Seroprevalence of N-methyl-d-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264(6):545-550.
15. Butters M.A., Young J.B., Lopez O., Aizenstein H.J., Mulsant B.H., Reynolds C.F., DeKosky S.T., Becker J.T. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialog. Clin. Neurosci. 2008, 10:345-357.
16. Calabrese B., Shaked G.M., Tabarean I.V., Braga J., Koo E.H., Halpain S. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol. Cell. Neurosci. 2007, 35:183-193.
17. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:183-189.
18. Cummings J.L. Depression in vascular dementia. Hillside J. Clin. Psychiatry 1988, 10:209-231.
19. Dal Forno G., Palermo M.T., Donohue J.E., Karagiozis H., Zonderman A.B., Kawas C.H. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann. Neurol. 2005, 57:381-387.
20. Dalfo E., Albasanz J.L., Martin M., Ferrer I. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions. Brain Pathol. (Zurich, Switzerland) 2004, 14:388-398.
21. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., Dessain S.K., Rosenfeld M.R., Balice-Gordon R., Lynch D.R. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008, 7:1091-1098.
22. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011, 10:63-74.
23. Dalmau J., Tuzun E., Wu H.Y., Masjuan J., Rossi J.E., Voloschin A., Baehring J.M., Shimazaki H., Koide R., King D., Mason W., Sansing L.H., Dichter M.A., Rosenfeld M.R., Lynch D.R. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 2007, 61:25-36.
24. Dambinova S.A., Khounteev G.A., Skoromets A.A. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke: J. Cereb. Circul. 2002, 33:1181-1182.
25. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
26. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
27. Dotson V.M., Beydoun M.A., Zonderman A.B. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010, 75:27-34.
28. Emmer B.J., van der Grond J., Steup-Beekman G.M., Huizinga T.W., van Buchem M.A. Selective involvement of the amygdala in systemic lupus erythematosus. PLoS Med. 2006, 3:e499.
29. Fragoso-Loyo H., Cabiedes J., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Diamond B., Llorente L., Sanchez-Guerrero J. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PloS ONE 2008, 3:e3347.
30. Gable M.S., Gavali S., Radner A., Tilley D.H., Lee B., Dyner L., Collins A., Dengel A., Dalmau J., Glaser C.A. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:1421-1429.
31. Gingrich M.B., Traynelis S.F. Serine proteases and brain damage - is there a link?. Trends Neurosci. 2000, 23:399-407.
32. Gordon-Krajcer W., Salinska E., Lazarewicz J.W. N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro--superfusion study. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre. Polish Acad. Sci. 2002, 40:13-17.
33. Hacohen Y., Wright S., Waters P., Agrawal S., Carr L., Cross H., De Sousa C., Devile C., Fallon P., Gupta R., Hedderly T., Hughes E., Kerr T., Lascelles K., Lin J.P., Philip S., Pohl K., Prabahkar P., Smith M., Williams R., Clarke A., Hemingway C., Wassmer E., Vincent A., Lim M.J. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J. Neurol. Neurosurg. Psychiatry 2013, 84:748-755.
34. Hammer C., Stepniak B., Schneider A., Papiol S., Tantra M., Begemann M., Siren A.L., Pardo L.A., Sperling S., Mohd Jofrry S., Gurvich A., Jensen N., Ostmeier K., Luhder F., Probst C., Martens H., Gillis M., Saher G., Assogna F., Spalletta G., Stocker W., Schulz T.F., Nave K.A., Ehrenreich H. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry 2013, 18(9):993-1005.
35. Hanly J.G., Robichaud J., Fisk J.D. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol. 2006, 33:1553-1558.
36. Hansen H.C., Klingbeil C., Dalmau J., Li W., Weissbrich B., Wandinger K.P. Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013, 70:117-119.
37. Harciarek M., Jodzio K. Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review. Neuropsychol. Rev. 2005, 15:131-145.
38. Harris J.A., Devidze N., Halabisky B., Lo I., Thwin M.T., Yu G.Q., Bredesen D.E., Masliah E., Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 2010, 30:372-381.
39. Hijmans W., Radl J., Bottazzo G.F., Doniach D. Autoantibodies in highly aged humans. Mech. Ageing Dev. 1984, 26:83-89.
40. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.L., Ashe K.H., Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
41. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
42. Hughes E.G., Peng X., Gleichman A.J., Lai M., Zhou L., Tsou R., Parsons T.D., Lynch D.R., Dalmau J., Balice-Gordon R.J. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 2010, 30:5866-5875.
43. Husebye E.S., Sthoeger Z.M., Dayan M., Zinger H., Elbirt D., Levite M., Mozes E. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64:1210-1213.
44. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., Friese M.A., Galea I., Kullmann D.M., Beeson D., Lang B., Bien C.G., Vincent A. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
45. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
46. Jeste D.V., Finkel S.I. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am. J. Geriatr. Psychiatry 2000, 8:29-34.
47. Jorm A.F. History of depression as a risk factor for dementia: an updated review. Aust. N. Z. J. Psychiatry 2001, 35:776-781.
48. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
49. Kowal C., Degiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., Diamond B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19854-19859.
50. Kunik M.E., Graham D.P., Snow-Turek A.L., Molinari V.A., Orengo C.A., Workman R.H. Contribution of cognitive impairment, depression, and psychosis to the outcome of agitated geropsychiatric inpatients with dementia. J. Nerv. Ment. Dis. 1998, 186:299-303.
51. Kwon H.B., Sabatini B.L. Glutamate induces de novo growth of functional spines in developing cortex. Nature 2011, 474:100-104.
52. Lanz T.A., Carter D.B., Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol. Dis. 2003, 13:246-253.
53. Lapteva L., Nowak M., Yarboro C.H., Takada K., Roebuck-Spencer T., Weickert T., Bleiberg J., Rosenstein D., Pao M., Patronas N., Steele S., Manzano M., van der Veen J.W., Lipsky P.E., Marenco S., Wesley R., Volpe B., Diamond B., Illei G.G. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2505-2514.
54. Lau C.G., Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. 2007, 8:413-426.
55. Leroi I., Voulgari A., Breitner J.C., Lyketsos C.G. The epidemiology of psychosis in dementia. Am. J. Geriatr. Psychiatry 2003, 11:83-91.
56. Manoussakis M.N., Tzioufas A.G., Silis M.P., Pange P.J., Goudevenos J., Moutsopoulos H.M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin. Exp. Immunol. 1987, 69:557-565.
57. Marcello E., Gardoni F., Mauceri D., Romorini S., Jeromin A., Epis R., Borroni B., Cattabeni F., Sala C., Padovani A., Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J. Neurosci. 2007, 27:1682-1691.
58. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst. Rev. 2006, CD003154.
59. Mota S.I., Ferreira I.L., Rego A.C. Dysfunctional synapse in Alzheimer's disease - a focus on NMDA receptors. Neuropharmacology 2014, 76(Pt A):16-26.
60. Newcomer J.W., Farber N.B., Olney J.W. NMDA receptor function, memory, and brain aging. Dialog. Clin. Neurosci. 2000, 2:219-232.
61. Olivares D., Deshpande V.K., Shi Y., Lahiri D.K., Greig N.H., Rogers J.T., Huang X. N-methyl d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr. Alzheimer Res. 2012, 9:746-758.
62. Parsons C.G., Gilling K. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods Mol. Biol. (Clifton, NJ) 2007, 403:15-36.
63. Parsons C.G., Gruner R., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993, 32:1337-1350.
64. Peng D., Yuan X., Zhu R. Memantine hydrochloride in the treatment of dementia subtypes. J. Clin. Neurosci. 2013, 20:1482-1485.
65. Probst C., Komorowski L., Dähnich C., Rosemann A., Schlumberger W., Wandinger K.P., Mothes T., Stöcker W. Designer antigens as diagnostic targets for (auto)antibody determination. From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies 2007, 5:619-632. Pabst Science Publisher.
66. Pruss H., Finke C., Holtje M., Hofmann J., Klingbeil C., Probst C., Borowski K., Ahnert-Hilger G., Harms L., Schwab J.M., Ploner C.J., Komorowski L., Stoecker W., Dalmau J., Wandinger K.P. N-methyl-d-aspartate receptor antibodies in herpes simplex encephalitis. Ann. Neurol. 2012, 72:902-911.
67. Pruss H., Holtje M., Maier N., Gomez A., Buchert R., Harms L., Ahnert-Hilger G., Schmitz D., Terborg C., Kopp U., Klingbeil C., Probst C., Kohler S., Schwab J.M., Stoecker W., Dalmau J., Wandinger K.P. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 78:1743-1753.
68. Ramanathan S., Mohammad S.S., Brilot F., Dale R.C. Autoimmune encephalitis: recent updates and emerging challenges. J. Clin. Neurosci. 2014, 21:722-730.
69. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (New York, NY) 2007, 316:750-754.
70. Rosen J., Zubenko G.S. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol. Psychiatry 1991, 29:224-232.
71. Sabbagh M.N., Hake A.M., Ahmed S., Farlow M.R. The use of memantine in dementia with Lewy bodies. J. Alzheimers Dis. 2005, 7:285-289.
72. Sakai K., Yamane Y., Yamamoto Y., Maeda K. Depression in dementia with Lewy bodies. Seishin shinkeigaku zasshi - Psychiatria et neurologia Japonica 2013, 115:1127-1134.
73. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacool. Toxicol. 2003, 43:545-584.
74. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
75. Shrestha B.R., Vitolo O.V., Joshi P., Lordkipanidze T., Shelanski M., Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol. Cell. Neurosci. 2006, 33:274-282.
76. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.G., Vielhaber S., Kastner A., Skalej M., Jordan W., Schiltz K., Klingbeil C., Wandinger K.P., Bogerts B., Stoecker W. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry (Chicago, IL) 2012, 70:271-278.
77. Stöcker W. Rationelle Histochemie mit einer neuen Mikroanalysemethode. Acta Histochem. 1985, 31:269-281.
78. Swanberg M.M. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis. Assoc. Disord. 2007, 21:164-166.
79. Verges D.K., Restivo J.L., Goebel W.D., Holtzman D.M., Cirrito J.R. Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo. J. Neurosci. 2011, 31:11328-11337.
80. Verkaik R., Francke A.L., van Meijel B., Ribbe M.W., Bensing J.M. Comorbid depression in dementia on psychogeriatric nursing home wards: which symptoms are prominent?. Am. J. Geriatr. Psychiatry 2009, 17:565-573.
81. Wandinger K.P., Saschenbrecker S., Stoecker W., Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J. Neuroimmunol. 2011, 231:86-91.
82. Wang X., Shen Y., Chen W. Progress in frontotemporal dementia research. Am. J. Alzheimers Dis. Other Demen. 2013, 28:15-23.
83. Xu C.L., Liu L., Zhao W.Q., Li J.M., Wang R.J., Wang S.H., Wang D.X., Liu M.Y., Qiao S.S., Wang J.W. Anti-N-methyl-d-aspartate receptor encephalitis with serum anti-thyroid antibodies and IgM antibodies against Epstein-Barr virus viral capsid antigen: a case report and one year follow-up. BMC Neurol. 2011, 11:149.
84. Yoshio T., Onda K., Nara H., Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2006, 54:675-678.